Author: Site Editor Publish Time: 2026-11-13 Origin: Site
China Proposes Tiered Market Exclusivity for Rare Disease and Pediatric Drugs
On 19 October 2026, the National Medical Products Administration (NMPA) released the draft Implementation Measures for Drug Market Exclusivity for public comment, open until 18 November 2026. The measures implement Article 21 of the Implementing Regulations of the Drug Administration Law and specify who qualifies, how long protection lasts, how to apply, and how the period is executed. Under the draft, rare disease drugs would receive seven, five or four years depending on the category, and pediatric drugs two or one year. During the exclusivity period NMPA would not approve other applicants' marketing or supplemental applications for the same variety. The text remains a draft; the final version will govern.
Market exclusivity is defined as a period of exclusivity that NMPA grants, on application, to qualifying products. The measures would apply to traditional Chinese medicines, chemical drugs and therapeutic biologics.
A rare disease drug is one whose approved indication falls within the National Health Commission's Rare Disease Catalogue and which either has no effective treatment available in China or offers a significant clinical benefit over existing therapy. Products outside the catalogue can also qualify where an expert panel confirms low prevalence, high disease burden and substantial clinical benefit.
A pediatric drug is one developed for children with an explicit pediatric indication or pediatric dosing in its label. "Same variety" is defined strictly: identical generic name, active ingredient or TCM formula, dosage form and indication. For a pediatric product granted exclusivity on a new strength, the strength itself must also match before a product is treated as the same variety — a deliberate limit on how far the protection reaches.
Rare disease drugs
7 years — innovative drugs, and originator drugs already marketed overseas, launched in China
5 years — improved new drugs
4 years — generics or biologics of overseas-marketed products first launched in China, or a first Chinese approval of a rare disease indication already marketed overseas
Pediatric drugs
2 years — innovative drugs and originator drugs already marketed overseas, launched in China
1 year — a marketed product adding a pediatric indication, a pediatric dosage form or a pediatric strength for the first time; these three routes require the corresponding pediatric clinical trials
Where a product qualifies for both rare disease and pediatric exclusivity, the applicant must choose one.
Exclusivity is requested together with the marketing application, and only one period may be requested per application. If different indications of the same product obtain exclusivity at different times, each period is calculated separately.
Where no regulatory data protection applies, the period runs from the date of marketing approval. Where data protection has been or is simultaneously granted — most often for pediatric products — the exclusivity is stacked after the data protection period and begins the day after it expires. NMPA records the period and its start and end dates in the approval certificate, and the Center for Drug Evaluation publishes it.
Filing and technical review of same-variety products are not suspended. What is blocked is approval: other applicants may submit and be reviewed, but in principle cannot be approved until the period expires.
Rare disease applicants must commit to maintaining supply and to avoiding discontinuation. NMPA may terminate exclusivity where the marketing authorization is revoked, withdrawn or cancelled, where the holder fails to honor the supply commitment, or where the authorities require it during a public health emergency.
The linkage is deliberate: exclusivity is a conditional administrative protection, not an unconditional commercial reward. A company that uses the period to withdraw from the market loses it.
Market exclusivity is often read as an extension of patent protection. It is a separate regime. Patents protect an invention and are enforced through the courts and the patent linkage mechanism; regulatory data protection protects the undisclosed data package; market exclusivity restricts approval of same-variety products regardless of whose data is used. Each has its own term, its own trigger and its own exceptions, and they can run in sequence on the same product.
What this means for partners Beyond the incentive itself, the draft brings market exclusivity into product selection and filing strategy as a factor to be screened, not a bonus discovered late.
For generic developers, the relevant question at portfolio review is no longer only patent status and data protection. It is whether the reference product, or another same-variety product in the queue, may obtain exclusivity — and what that does to the expected approval date and to the commercial case built on it.
For rare disease and pediatric programmes, the assessment is broader: clinical value, eligibility under a narrow definition, the evidence package the application will need, and the supply capability the commitment implies. A seven-year period is worth little to a company that cannot guarantee continued supply.
Bestcomm will continue to track the draft and the final implementing rules, and will reflect them in its development and regulatory practice, so that partners can identify development and market-access risk earlier.
When does the consultation close?
Comments are open until 18 November 2026. The draft is not in force; the final measures may differ in scope, periods or procedure.
Does exclusivity block other companies from filing?
No. Same-variety applications can still be submitted and reviewed. Approval is what is withheld until the period expires.
Can rare disease and pediatric exclusivity be combined?
No. Where a product meets the conditions for both, the applicant must choose one. Only one period may be requested per marketing application.
How does it interact with data protection?
For products that also hold regulatory data protection, exclusivity is stacked after that period and starts the following day. The two run consecutively, not concurrently.
The draft does not create a new incentive out of nothing — it turns an existing principle in the Drug Administration Law Implementing Regulations into an operational procedure with definitions, deadlines and termination clauses. For companies planning China filings, the value lies less in the headline durations than in the screening question they force: who else in this product line could hold the market, and until when.
Source: National Medical Products Administration, Implementation Measures for Drug Market Exclusivity (Draft for Comment), released 19 October 2026; consultation open to 18 November 2026.
